Selected characteristics of OSCC patients by whether QOL was available during each of the three time periods used for this study, University of Washington Affiliated Hospitals, Seattle, WA, 2003–2010
| Characteristic | Pre-treatment QOL data available? |
Immediate post- treatment QOL data available? |
One year post- treatment QOL data available? |
|||
|---|---|---|---|---|---|---|
| No (n=30) |
Yes (n=198) |
No* (n=115) |
Yes (n=84) |
No** (n=101) |
Yes (n=81) |
|
| Age, mean | 59 | 60 | 58 | 60 | 58 | 59 |
| Male | 19 (63%) | 137 (69%) | 77 (67%) | 58 (69%) | 67 (66%) | 55 (68%) |
| White | 28 (93%) | 179 (90%) | 12 (10%) | 8 (10%) | 87 (86%) | 76 (94%) |
| High-risk HPV DNA | 11 (37%) | 55 (28%) | 31 (27%) | 30 (36%) | 32 (32%) | 24 (29%) |
| Tumor site | ||||||
| Oral | 25 (83%) | 141 (71%) | 89 (75%) | 57 (68%) | 73 (73%) | 56 (69%) |
| Oropharyngeal | 5 (17%) | 57 (29%) | 29 (25%) | 27 (32%) | 28 (28%) | 25 (31%) |
| T stage | ||||||
| 1 | 11 (37%) | 70 (35%) | 41 (36%) | 39 (46%) | 37 (37%) | 38 (47%) |
| 2 | 10 (33%) | 59 (30%) | 36 (31%) | 26 (31%) | 30 (30%) | 28 (35%) |
| 3–4 | 9 (30%) | 69 (35%) | 38 (33%) | 19 (23%) | 34 (34%) | 15 (19%) |
| N stage | ||||||
| 0 | 17 (57%) | 95 (48%) | 61 (53%) | 46 (55%) | 57 (56%) | 44 (54%) |
| 1 | 2 (7%) | 25 (13%) | 17 (15%) | 7 (8%) | 12 (12%) | 9 (11%) |
| 2–3 | 11 (37%) | 78 (39%) | 37 (32%) | 31 (37%) | 32 (32%) | 28 (35%) |
| Cigarette smoking | ||||||
| Never | 7 (23%) | 51 (26%) | 31 (27%) | 19 (23%) | 24 (24%) | 24 (30%) |
| Former | 8 (27%) | 59 (30%) | 33 (29%) | 28 (33%) | 31 (31%) | 25 (31%) |
| Current | 15 (50%) | 88 (44%) | 51 (44%) | 37 (44%) | 46 (46%) | 32 (40%) |
| Alcohol drinking | ||||||
| Never | 3 (10%) | 18 (9%) | 8 (7%) | 11 (13%) | 10 (10%) | 7 (9%) |
| Former | 7 (23%) | 55 (28%) | 31 (27%) | 24 (29%) | 26 (26%) | 23 (28%) |
| 0–14 drinks/week | 10 (33%) | 62 (31%) | 33 (29%) | 26 (31%) | 30 (30%) | 25 (31%) |
| >14 drinks/week | 10 (33%) | 63 (32%) | 43 (37%) | 23 (27%) | 35 (35%) | 26 (32%) |
| Comorbidity† | ||||||
| 0 | 9 (30%) | 42 (21%) | 26 (23%) | 23 (27%) | 28 (28%) | 18 (22%) |
| 1 | 14 (47%) | 85 (43%) | 50 (43%) | 35 (42%) | 39 (39%) | 38 (47%) |
| 2–3 | 7 (23%) | 71 (36%) | 39 (34%) | 26 (31%) | 34 (34%) | 25 (31%) |
| Multimodality therapy | 13 (43%) | 114 (58%) | 65 (57%) | 44 (52%) | 56 (55%) | 42 (52%) |
| Surgery to primary site | 28 (93%) | 179 (90%) | 105 (91%) | 75 (89%) | 93 (92%) | 74 (91%) |
| Chemotherapy | 9 (30%) | 71 (36%) | 41 (36%) | 28 (33%) | 35 (35%) | 24 (30%) |
| Radiation therapy | 13 (43%) | 119 (60%) | 68 (59%) | 46 (55%) | 60 (60%) | 43 (53%) |
Only includes patients who were also alive 8 months after treatment started.
Only includes patients who were also alive 15 months after treatment started
Comorbidity assessed with ACE-27, with higher scores indicating greater comorbidity.
There were no differences in mean age or the number of patients in each of the above categories when comparing whether QOL was available during the three time periods.
Abbreviations: ACE-27: Adult Comorbidity Evaluation-27; HPV: Human Papillomavirus; OSCC: Oral cavity and oropharyngeal squamous cell carcinoma; QOL: Quality of life